Dinutuximab (Anti-GD2) is a chimeric mouse/human monoclonal antibody that targets ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. It has potential antineoplastic activity. MW: 145.5 KD.